Ubrogepant | hsa00520 | Amino sugar and nucleotide sugar metabolism | 2.24E-02 | 3 | Q16222, Q9Y223, P06865 | UAP1, GNE, HEXA | More | |
Ubrogepant | hsa00524 | Neomycin, kanamycin and gentamicin biosynthesis | 2.03E-02 | 1 | P35557 | GCK | More | |
Ubrogepant | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 1.91E-02 | 1 | Q9NY97 | B3GNT2 | More | |
Ubrogepant | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | |
Ubrogepant | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | |
Ubrogepant | hsa00601 | Glycosphingolipid biosynthesis - lacto and neolacto series | 3.78E-02 | 1 | Q9NY97 | B3GNT2 | More | |
Ubrogepant | hsa00630 | Glyoxylate and dicarboxylate metabolism | 4.46E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | |
Ubrogepant | hsa00730 | Thiamine metabolism | 1.15E-03 | 2 | Q9Y6K8, P24666 | AK5, ACP1 | More | |
Ubrogepant | hsa00740 | Riboflavin metabolism | 4.03E-02 | 1 | P24666 | ACP1 | More | |
Ubrogepant | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.12E-02 | 1 | P14868 | DARS | More | |
Ubrogepant | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
Ubrogepant | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | |
Ubrogepant | hsa01210 | 2-Oxocarboxylic acid metabolism | 1.91E-02 | 1 | P50213 | IDH3A | More | |
Ubrogepant | hsa03013 | RNA transport | 2.99E-02 | 4 | P38919, P37198, P35658, P55884 | EIF4A3, NUP62, NUP214, EIF3B | More | |
Ubrogepant | hsa03040 | Spliceosome | 2.96E-02 | 5 | O60508, P08579, Q07955, Q01130, Q9Y2W2 | CDC40, SNRPB2, SFRS1, SFRS2, WBP11 | More | |
Ubrogepant | hsa03050 | Proteasome | 4.83E-02 | 1 | P55036 | PSMD4 | More | |
Ubrogepant | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | |
Ubrogepant | hsa04014 | Ras signaling pathway | 2.54E-02 | 5 | P42338, P20827, P49767, Q13009, P50151 | PIK3CB, EFNA1, VEGFC, TIAM1, GNG10 | More | |
Ubrogepant | hsa04151 | PI3K-Akt signaling pathway | 1.14E-02 | 8 | P42338, P43657, P20827, P49767, P50151, O15335, Q13751, P14784 | PIK3CB, P2RY5, EFNA1, VEGFC, GNG10, CHAD, LAMB3, IL2RB | More | |
Ubrogepant | hsa04330 | Notch signaling pathway | 2.77E-02 | 2 | Q92542, P49768 | NCSTN, PSEN1 | More | |
Ubrogepant | hsa04390 | Hippo signaling pathway | 4.35E-02 | 2 | P63261, O15105 | ACTG1, SMAD7 | More | |
Ubrogepant | hsa04530 | Tight junction | 3.60E-03 | 5 | P63261, P16989, P56750, Q92974, Q14247 | ACTG1, CSDA, CLDN17, ARHGEF2, CTTN | More | |
Ubrogepant | hsa04610 | Complement and coagulation cascades | 3.16E-03 | 2 | P00734, P0C0L4 | F2, C4A | More | |
Ubrogepant | hsa04612 | Antigen processing and presentation | 4.78E-02 | 6 | P48382, P26715, P26717, Q13241, O43908, P01375 | RFX5, KLRC1, KLRC2, KLRD1, KLRC4, TNF | More | |
Ubrogepant | hsa04613 | Neutrophil extracellular trap formation | 1.73E-02 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
Ubrogepant | hsa04621 | NOD-like receptor signaling pathway | 2.27E-02 | 9 | Q9H1Y0, P43490, O00463, Q05823, P01375, P49913, P59665, P59666, P12838 | ATG5, PBEF1, TRAF5, RNASEL, TNF, CAMP, DEFA1; DEFA1B, DEFA3, DEFA4 | More | |
Ubrogepant | hsa04650 | Natural killer cell mediated cytotoxicity | 1.25E-02 | 8 | P01375, O60880, P20963, Q13241, P26718, O75015, P26717, P26715 | TNF, SH2D1A, CD247, KLRD1, KLRK1, FCGR3B, KLRC2, KLRC1 | More | |
Ubrogepant | hsa04662 | B cell receptor signaling pathway | 9.78E-04 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | |
Ubrogepant | hsa04664 | Fc epsilon RI signaling pathway | 1.82E-02 | 3 | P42338, P07948, P09917 | PIK3CB, LYN, ALOX5 | More | |
Ubrogepant | hsa04724 | Glutamatergic synapse | 3.24E-02 | 3 | P43003, P50151, P15104 | SLC1A3, GNG10, GLUL | More | |
Ubrogepant | hsa04950 | Maturity onset diabetes of the young | 2.03E-02 | 1 | P35557 | GCK | More | |
Ubrogepant | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
Ubrogepant | hsa05133 | Pertussis | 2.24E-02 | 2 | P0DP23, P0C0L4 | CALM1, C4A | More | |
Ubrogepant | hsa05143 | African trypanosomiasis | 4.81E-02 | 2 | P69905, P68871 | HBA2, HBB | More | |
Ubrogepant | hsa05144 | Malaria | 3.12E-02 | 4 | P60033, P01375, P35443, P26718 | CD81, TNF, THBS4, KLRK1 | More | |
Ubrogepant | hsa05145 | Toxoplasmosis | 3.96E-02 | 2 | P28068, Q16787 | HLA-DMB, LAMA3 | More | |
Ubrogepant | hsa05150 | Staphylococcus aureus infection | 1.02E-03 | 7 | P21730, P21462, O75015, P59665, P59666, P12838, P49913 | C5AR1, FPR1, FCGR3B, DEFA1; DEFA1B, DEFA3, DEFA4, CAMP | More | |
Ubrogepant | hsa05165 | Human papillomavirus infection | 2.01E-02 | 3 | Q16787, Q02930, Q13315 | LAMA3, CREB5, ATM | More | |
Ubrogepant | hsa05166 | Human T-cell leukemia virus 1 infection | 2.91E-02 | 3 | Q02930, P28068, Q13315 | CREB5, HLA-DMB, ATM | More | |
Ubrogepant | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | |
Ubrogepant | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
Ubrogepant | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |